Is BPC-157 Legal Now? Where FDA Stands After the 2026 Votes
BPC-157 came off FDA's restricted list and won an advisory committee vote in 2026. Here's what that changed, what it didn't, and when you might actually get a prescription.
Key takeaways
- In April 2026, FDA removed BPC-157 and 11 other peptides from its Category 2 list of substances that raise significant safety concerns.
- In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding BPC-157 to the 503A bulks list, for ulcerative colitis.
- That vote is a recommendation. Until FDA finishes rulemaking, licensed pharmacies still can't compound BPC-157.
- "Research use only" vials sold online are outside the medicine supply chain. The 2026 votes didn't change that.
How BPC-157 got restricted
BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice. It became popular for tendon, ligament and gut healing based mostly on animal studies. In late 2023, FDA placed it, along with about 18 other peptides, in Category 2 of its interim 503A bulks list. That category covers substances FDA says raise significant safety concerns, and in practice it cut off the legal compounding route.
What changed in 2026
After public pressure and a February 2026 announcement from HHS, FDA republished its interim list on April 15, 2026, removing BPC-157 and 11 other peptides from Category 2. FDA also scheduled its Pharmacy Compounding Advisory Committee (PCAC) to review seven of them.
On July 23 and 24, 2026, the committee voted to recommend adding six peptides to the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention. The committee voted against emideltide (DSIP). Five more peptides, including injectable GHK-Cu, are expected at a later meeting.
What the vote did not do
This is where most headlines get it wrong. Coming off Category 2 is not the same as being on Category 1, and a committee recommendation is not a rule. FDA generally follows PCAC recommendations, but adding a substance to the bulks list requires notice-and-comment rulemaking, and that process hadn't finished as of this writing. Until it does, a pharmacy compounding BPC-157 is in the same legal position it was in before the vote.
It's also worth noting what the committee actually reviewed. BPC-157 was evaluated for ulcerative colitis, not for orthopedic injuries, gut health in general, or anti-aging. FDA's own reviewers found little human data, and the committee voted the other way from FDA staff on several peptides.
What about "research use only" BPC-157?
Vials labeled "for research use only, not for human consumption" are sold outside the system that regulates medicines. There's no requirement that they contain what the label says, at the stated strength, free of contaminants. Selling them for human use is not legal, and the 2026 votes didn't change that. We don't recommend them, and our AI won't help anyone source or dose them.
Athletes, take note
BPC-157 and TB-500 are prohibited at all times under the World Anti-Doping Code. A future compounding pathway won't change that for tested athletes.
When could you get a prescription?
Nobody can give a firm date. The realistic path is: FDA publishes a proposed rule, takes public comment, then finalizes it. After that, licensed 503A pharmacies can compound BPC-157 for patients with a valid prescription from a clinician who decides it's appropriate. Even then, it will be a compounded drug, not an FDA-approved one.
If you want to know the day that changes, join the BPC-157 waitlist. In the meantime, our clinicians can talk through recovery options that can be prescribed today, and the labs worth checking first.
Have a question this didn't answer?
Ask the peptide AI for a straight answer, or start a 3-minute assessment and a licensed clinician will review it.
Frequently asked questions
Is BPC-157 legal in 2026?
It's no longer on FDA's Category 2 restricted list, and an FDA advisory committee recommended it for the 503A bulks list in July 2026. But until FDA completes rulemaking, licensed pharmacies still cannot compound it.
Did FDA approve BPC-157?
No. Even after the bulks-list process finishes, BPC-157 would be a compounded medication, not an FDA-approved drug.
Can I buy research-use-only BPC-157?
Those products are sold outside the regulated medicine supply chain and aren't legal to sell for human use. Quality and contents aren't verified. We don't recommend them.
What did the committee review BPC-157 for?
Ulcerative colitis. It was not evaluated for injuries, general gut health or anti-aging.
Is BPC-157 banned in sports?
Yes. BPC-157 and TB-500 are prohibited at all times under the World Anti-Doping Code.
Sources
- McDermott Will & Schulte: Bulk-list bound? PCAC backs majority of peptides (July 2026)
- Frier Levitt: FDA advisory committee recommends six peptides for 503A compounding (Sept 2026)
- Goodwin via Mondaq: FDA signals evolving stance toward compounding of certain peptides (April 2026)
- Pharmacy Times: What the peptide vote actually changes (July 2026)
- Black Health: BPC-157 and TB-500, what the FDA peptide vote changed
This article is for education only and isn't medical advice. Peptides discussed may not be FDA-approved for these uses, and compounded medications are not FDA-approved. Talk with a licensed clinician before starting any therapy.